ABCG5 Inhibitors

ABCG5 inhibitors encompass a diverse range of chemicals that indirectly modulate the function and activity of ABCG5, a transporter protein involved in the excretion of dietary cholesterol and plant sterols. These inhibitors primarily function by targeting cholesterol metabolism, bile acid pathways, or related signaling processes that are crucial for ABCG5's role in cholesterol homeostasis. Compounds such as Ezetimibe, which inhibits intestinal absorption of cholesterol, and bile acid sequestrants like Cholestyramine and Colesevelam, can indirectly affect ABCG5 activity by reducing the need for cholesterol excretion or by altering bile acid recycling.

Furthermore, a series of HMG-CoA reductase inhibitors, including Lovastatin, Simvastatin, Atorvastatin, and Rosuvastatin, play a significant role in reducing cholesterol synthesis, thereby potentially influencing ABCG5's function in cholesterol transport. PPARα agonists like Fenofibrate and Gemfibrozil modulate lipid metabolism, which can have implications on ABCG5-mediated cholesterol transport. Additionally, Niacin, known for its effects on lipid metabolism, and Ursodeoxycholic acid, which modifies bile acid composition, represent other mechanisms through which ABCG5 activity can be indirectly impacted. Plant sterols, competing with dietary cholesterol for absorption, can also reduce the functional demand on ABCG5 for cholesterol excretion.